Postexposure vaccination with a virion host shutoff defective mutant reduces UV-B radiation-induced ocular herpes simplex virus shedding in mice

Vaccine

Volumn 16, Issue 1, 1998, Pages 6-8

  Walker, Joy ^a   Laycock, Keith A ^a   Pepose, Jay S ^a   Leib, David A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HSV; Latency; Vaccine

Indexed keywords

HERPES SIMPLEX VACCINE; HERPES VACCINE; LIVE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HERPES; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; LATENT PERIOD; MOUSE; NONHUMAN; OPHTHALMOLOGY; PRIORITY JOURNAL; ULTRAVIOLET B RADIATION; ULTRAVIOLET RADIATION; VACCINATION; VIRION; VIRUS MUTANT; VIRUS SHEDDING;

ANIMALS; EYE; EYE INFECTIONS; HERPES SIMPLEX; MICE; MICE, INBRED STRAINS; SIMPLEXVIRUS; ULTRAVIOLET RAYS; VACCINES, ATTENUATED; VIRAL PROTEINS; VIRAL VACCINES; VIRUS SHEDDING;

EID: 0031986467     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00177-1     Document Type: Article

References (21)

1. Dawson C.R., Togni B. Herpes simplex eye infections, clinical manifestation, pathogenesis and management. Survey of Ophthalmology. 21:1976;121-135.
2. Honess R.W., Roizman B. Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. Journal of Virology. 14:1974;8-19.
3. Stevens J.G., Wagner E.K., Devi-Rao G., Cook M.L., Feldman L. RNA complementary to herpesvirus α-gene mRNA is predominant in latently infected neurons. Science. 235:1987;1056-1059.
4. Stanberry L.R. Herpes simplex virus vaccines as immunotherapeutic agents. Trends in Microbiology. 3:1995;244-247.
5. McKenzie R., Straus S. Therapeutic immunization for recurrent herpes simplex virus infections. Advances in Experimental Medicine and Biology. 394:1996;67-83.
6. Burke R.L., Goldbeck C., Ng P., Stanberry L., Ott G., Van Nest G. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. Journal of Infectious Diseases. 170:1994;1110-1119.
7. Nakao M., Hazama M., Mayumi-Aono A., Hinuma S., Fijisawa Y. Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein D-interleukin-2 fusion protein. Journal of Infectious Diseases. 169:1994;787-791.
8. Nesburn A.B., Burke R.L., Ghiasi H., Slanina S., Bahri S., Wechsler S.L. Vaccine therapy for ocular herpes simplex virus (HSV) infection: Periocular vaccination reduces spontaneous ocular HSV type shedding in latently infected rabbits. Journal of Virology. 68:1994;5084-5092.
9. Stanberry L.R., Burke R.L., Myers M.G. Herpes simplex virus glycoprotein treatment of recurrent genital herpes. Journal of Infectious Diseases. 157:1988;156-163.
10. Straus S.E., Corey L., Burke R., Savarese B., Barnum G., Krause P.R., Khost R.G., Meier J.L., Sekulovich R., Adair S.F., Dekker C.L. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet. 343:1994;1460-1463.
11. Becker Y., Tavor E., Asher Y., Berkowitz C., Moyal M. Effect of herpes simplex virus type-1 UL41 gene on the stability of mRNA from the cellular genes: β-actin, fibronectin, glucose transporter-1, and docking protein, and on virus intraperitoneal pathogenicity to newborn mice. Virus Genes. 7:1993;133-143.
12. Strelow L.I., Leib D.A. Role of the virion host shutoff (vhs) of herpes simplex virus type 1 in latency and pathogenesis. Journal of Virology. 69:1995;6779-6786.
13. Strelow L.I., Leib D.A. Analysis of conserved domains of UL41 of herpes simplex virus type 1 in virion host shutoff and pathogenesis. Journal of Virology. 70:1996;5665-5667.
14. Oroskar A.A., Read G.S. A mutant of herpes simplex virus type 1 exhibits increased stability of immediate-early (alpha) mRNAs. Journal of Virology. 61:1987;604-606.
15. Banks T.A., Nair S., Rouse B.T. Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus. Journal of Virology. 67:1993;613-616.
16. Berthommé H., Jacquemont B., Epstein A. The pseudorabies virus host-shutoff homolog gene: nucleotide sequence and comparison with alphaherpesvirus protein counterparts. Virology. 193:1993;1028-1032.
17. Laycock K.A., Lee S.F., Brady R.H., Pepose J.S. Characterization of a murine model of recurrent herpes simplex viral keratitis induced by ultraviolet B radiation. Investigations in Opthalmology and Visual Sciences. 32:1991;2741-2746.
18. Morrison L.A., Knipe D.M. Immunization with replication-defective mutants of herpes simplex virus type 1: Sites of immune intervention in pathogenesis of challenge virus infection. Journal of Virology. 68:1994;689-696.
19. Keadle, T.L., Laycock, K.A., Miller, J.K., Hook, K.K., Fenoglio, E.D., Francotte, M., Slaoui, M., Stuart, P.M. and Pepose, J.S., Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice. Journal of Infectious Diseases, 1997, in press.
20. Walker J., Leib D.A. Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion bost shutoff function. Vaccine. 16:1998;1-8.
21. Whitley R.J., Kern E.R., Chatterjee S., Chou J., Roizman B. Replication, establishment of latency, and induced reactivation of herpes simplex virus γ34.5 deletion mutants in rodent models. Journal of Clinical Investigation. 91:1993;2837-2843.